Quiz-summary
0 of 15 questions completed
Questions:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Information
You have already completed the module before. Hence you can not start it again.
Module is loading…
You have to finish following quiz, to start this quiz:
Results
Results
Time has elapsed
Categories
- Not categorized 0%
-
Thank you, we will review your submission and notify you of your results via email.
If not received within 5 hours due to spam, don’t worry, it will show in your profile.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- Answered
- Review
- Question 1 of 15
1. Question
1. Which of the listed factors are important to modifying cardiovascular risk in T2DM?
- Question 2 of 15
2. Question
2. Which statement is true? DPP-4 inhibitor CVOTs:
- Question 3 of 15
3. Question
3. Which statement is true?
- Question 4 of 15
4. Question
4. In EMPA-REG OUTCOME, empagliflozin significantly reduced three-point MACE by __%:
- Question 5 of 15
5. Question
5. In EMPA-REG OUTCOME, empagliflozin significantly reduced cardiovascular death by __%:
- Question 6 of 15
6. Question
6. In EMPA-REG OUTCOME, empagliflozin significantly reduced hospitalisation for HF by __%:
- Question 7 of 15
7. Question
7. The CANVAS Program study of canagliflozin demonstrated a significant reduction in the primary three-point MACE endpoint, with each of the individual components demonstrating significant risk reduction.
- Question 8 of 15
8. Question
8. Which statement is true? Canagliflozin:
- Question 9 of 15
9. Question
9. Which of these best describes the study cohort of DECLARE-TIMI 58?
- Question 10 of 15
10. Question
10. In comparing baseline characteristics of study cohorts, DECLARE-TIMI 58 differed from EMPA-REG OUTCOME and the CANVAS Program in that:
- Question 11 of 15
11. Question
11. In DECLARE-TIMI 58, dapagliflozin demonstrated a significant 17% relative risk reduction for cardiovascular death and hospitalisation for HF.
- Question 12 of 15
12. Question
12. Meta-analysis of pooled SGLT-2 inhibitor CVOT datasets indicates a significantly reduced risk of hospitalisation for HF and cardiovascular death in patients:
- Question 13 of 15
13. Question
13. Real-world evidence from Scandinavian countries indicates that compared to DPP-4 inhibitors, dapagliflozin reduced risk for:
- Question 14 of 15
14. Question
14. ADA/EASD guidance for the treatment of T2DM with inadequate glycaemic control and where ASCVD predominates recommends:
- Question 15 of 15
15. Question
15. Which statement is false? ADA/EASD guidance for the treatment of T2DM with inadequate glycaemic control and without established ASCVD recommends:
Do you like this? Share with a colleague
[DISPLAY_ULTIMATE_SOCIAL_ICONS]